Lab Reagents
Human IgG antibody Laboratories manufactures the can uou trust sars 2 anyibody test reagents distributed by Genprice. The Can Uou Trust Sars 2 Anyibody Test reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Antibody. Other Can products are available in stock. Specificity: Can Category: Uou Group: Trust Sars
Trust Sars information
Mouse Calcineurin (CaN) ELISA Kit |
RDR-CaN-Mu-96Tests |
Reddot Biotech |
96 Tests |
EUR 890.4 |
Rat Calcineurin (CaN) ELISA Kit |
RDR-CaN-Ra-48Tests |
Reddot Biotech |
48 Tests |
EUR 669.6 |
Rat Calcineurin (CaN) ELISA Kit |
RDR-CaN-Ra-96Tests |
Reddot Biotech |
96 Tests |
EUR 931.2 |
Human Calcineurin (CaN) ELISA Kit |
RD-CaN-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 600 |
Human Calcineurin (CaN) ELISA Kit |
RD-CaN-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 830.4 |
Mouse Calcineurin (CaN) ELISA Kit |
RD-CaN-Mu-48Tests |
Reddot Biotech |
48 Tests |
EUR 613.2 |
Mouse Calcineurin (CaN) ELISA Kit |
RD-CaN-Mu-96Tests |
Reddot Biotech |
96 Tests |
EUR 850.8 |
Rat Calcineurin (CaN) ELISA Kit |
RD-CaN-Ra-48Tests |
Reddot Biotech |
48 Tests |
EUR 640.8 |
Rat Calcineurin (CaN) ELISA Kit |
RD-CaN-Ra-96Tests |
Reddot Biotech |
96 Tests |
EUR 890.4 |
3CL Protease (SARS-CoV-1 / SARS-CoV-2) Substrate |
79952-2 |
BPS Bioscience |
10 mg |
EUR 3460 |
Description: Sensitive internally quenched fluorogenic (FRET) substrate for SARS main protease with a Km value of 17 µM and a kcat value of 1.9 s»¹. |
SARS-CoV-2 Antigen Rapid Test Kit |
CoV2Ag-1 |
UnScience |
1T |
EUR 9.6 |
|
Description: This kit adopts the sandwich method and the technical principle of colloidal gold immunochromatography to qualitative determine the SARS-CoV-2 antigen. During the test, the sample is dropped into the sample well, and chromatography is performed under the capillary effect. The SARS-CoV-2 antigen in the sample combined with the colloidal goldlabeled SARS-CoV-2 monoclonal antibody I, and then spread to the test area. It is captured by another coated antibody (SARS-CoV-2 monoclonal antibody II), to form a complex and gather in the test area (T line). The quality control area is coated with the goat antimouse antibody, and the colloidal gold-labeled antibody is captured to form a complex and aggregate in the quality control area (C line). If the C line does not show color, it indicates that the result is invalid, and this sample needs to be tested again. |
SARS-CoV-2 Antigen Rapid Test Kit |
CoV2Ag-25 |
UnScience |
25T/kit |
EUR 42 |
|
Description: This product is used for in vitro qualitative detection of SARS-CoV-2 antigen in human oropharyngeal swabs, nasal swabs and nasopharyngeal swabs. It is helpful as an aid in the screening of early mild, asymptomatic, or acute patients for identification of SARS-CoV-2 infection. |
SARS-CoV-2 Rapid Antigen Test Nasal |
9901-NCOV-03G |
Roche Diagnostics |
25 Tests/Kit |
EUR 112.8 |
|
Description: The SARS-CoV-2 Rapid Antigen Test is a lateral fl ow rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen to SARS-CoV-2 present in human nasal samples. This test is intended for use as an aid in detection of SARS-CoV-2 infection in individuals suspected of COVID-19 with clinical symptoms onset within 5 days. Results are for the identification of SARS-CoV-2 nucleocapsid antigen. Antigen is generally detectable in human nasal swab samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co- infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The SARS-CoV-2 Rapid Antigen Test is intended for use in laboratory or POC settings by healthcare professionals, or self-collection under the supervision of a healthcare worke |
Spike (SARS-CoV-2) Lentivirus |
78010-2 |
BPS Bioscience |
500 µl x 2 |
EUR 2095 |
Description: Cell entry of SARS-CoV-2 depends on the binding of viral spike protein to cellular receptor ACE2. The SARS-CoV-2 Spike Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types mammalian cells, including primary and non-dividing cells. The particles contain the full length SARS-CoV-2 spike gene (QHD43416.1) driven by an EF1a promoter._x000D_ |
3CL Protease (SARS-CoV-2) |
100823-2 |
BPS Bioscience |
500 µg_x000D_ |
EUR 3360 |
Description: Severe acute respiratory Coronavirus 2 3C-like protease (SARS-CoV-2 3CL Protease), GenBank Accession No. YP_009725301, a.a. 1-306(full length), expressed in an E. coli expression system, MW=34 kDa. |
Shikari (Q-CAN) Canakinumab (Ilaris)Free drug ELISA kit |
CAN-FD-ILA |
Matriks Biotek |
1x96-wells test plate |
EUR 1053.6 |
Description: Enzyme Immunoassay for detection of freeCanakinumab (Ilaris) in human serum and plasma samples. |
PLPro, His-tag (SARS-CoV-2) |
100735-2 |
BPS Bioscience |
1 mg |
EUR 3000 |
Description: SARS-Cov-2 papain-like protease (PLPro), part of a large replicase polyprotein 1ab (E1564-Y1882), GenBank Accession No. QHD43415, with a N-terminal His-tag, expressed in an E. coli expression system. MW=38 kDa. |